Tag: MGROF

MustGrow Biologics Corp. (MGROF) – An Offering and Other Changes to Capital Structure

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, July 31, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Capital Structure. MustGrow announced a series of changes to be made to its capital structure including (i) a non-brokered private placement of up to 4,285,715 units of the Company (ii) the proposed repricing of outstanding share purchase warrants issued pursuant to its January 16, 2025 private placement and (iii) its intention to offer shares for debt settlement to all holders of unsecured convertible debentures issued pursuant to its January 16, 2025 private placement.

“LIFE” Offering. The 4,285,715 units will be offered at a price of CAD$0.70 per unit for gross proceeds of up to $3.0 million. Each unit will consist of one common share and one common share purchase warrant exercisable for 60 months at an exercise price of $0.90 per warrant. Net proceeds will be used for inventory production of TerraSante, inventory for agricultural products to sell via its Canadian distribution platform, NexusBioAg, and working capital and general corporate purposes.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – MustGrow Announces Non-Brokered LIFE Offering of up to $3 Million, Proposed Repricing of Warrants, and Shares for Debt Settlement Offer to Debentureholders

Posted on by aweinsoff@channelchek.com

Research News and Market Data MGROF

Jul 30, 2025 | News Releases

SASKATOON, Saskatchewan, Canada, July 30, 2025 – MustGrow Biologics Corp. (TSXV: MGRO; OTC: MGROF; FRA: 0C0) (the “Company” or “MustGrow“), is pleased to announce the following: (i) a non-brokered private placement of up to 4,285,715 units of the Company (each, a “Unit“) at a price of $0.70 per Unit for gross proceeds of up to $3,000,000 (the “LIFE Offering“); (ii) the proposed repricing of outstanding share purchase warrants issued pursuant to its January 16, 2025 private placement (the “Warrant Repricing“); and (iii) its intention to offer shares for debt settlement to all holders of unsecured convertible debentures issued pursuant to its January 16, 2025 private placement (the “Shares for Debenture Debt Settlement“).

LIFE Offering

Each Unit will consist of (i) one common share of the Company (a “Share“); and (ii) one common share purchase warrant (a “Warrant“). Each whole Warrant will be exercisable for a period of 60 months from the Closing Date (defined below) and will entitle the holder thereof to purchase one additional Share (a “Warrant Share“) at an exercise price of $0.90 per Warrant Share.

The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSanteTM, inventory for agricultural products to sell via its Canadian distribution platform NexusBioAg, and working capital and general corporate purposes.

Subject to the rules and policies of the TSX Venture Exchange (the “TSXV“), the securities issuable from the sale of Units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws. Insiders and certain consultants that participate in the LIFE Offering would be subject to a four-month hold period pursuant to applicable policies of the TSXV.

There is an offering document related to the LIFE Offering that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.MustGrow.ca. Prospective investors should read this offering document before making an investment decision.

It is expected that closing of the LIFE Offering will take place on or about August 21, 2025 or such other date(s) as may be determined by the Company (the “Closing Date“). Closing of the LIFE Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals, including the approval of the TSXV.

The Units sold pursuant to the LIFE Offering will be offered in Canada pursuant to the listed issuer financing exemption from the prospectus requirement available under Part 5A of National Instrument 45-106 – Prospectus Exemptions as modified by Coordinated Blanket Order 45-935 Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “LIFE Exemption“), in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933 (the “1933 Act”), as amended, and in certain other jurisdictions outside of Canada and the United States provided that no prospectus filing or comparable obligation arises in such other jurisdiction.

As consideration for services, certain eligible finders may receive (i) an aggregate cash fee equal up to 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by the finder; and (ii) non-transferable common share purchase warrants (the “Finder’s Warrants“) representing up to 6.0% of the aggregate number of Shares forming part of the Units issued to investors introduced to the Company by the finder. Each Finder’s Warrant will entitle its holder to purchase one Share (a “Finder Warrant Share“) at a price of $0.90 per Share for a 60-month period. The Finder Warrants and any Finder Warrant Shares issuable upon exercise thereof will be subject to a statutory hold period expiring four months and one day following the date of issue in accordance with applicable Canada securities laws.

Warrant Repricing

The Company intends to reprice an aggregate of 1,721,610 outstanding common share purchase warrants (the “Warrants“) issued pursuant to its January 16, 2025 private placement. The Warrants have an exercise price of $1.90 and an expiry date of January 16, 2030.

Provided the Company receives Warrant Amendment Approval (defined below), the Warrants will be deemed to be amended to adjust their exercise price to $0.90 per Share (the “Amended Warrants“). The Amended Warrants will also be amended to include an acceleration provision whereby, if for any ten (10) consecutive trading days (the “Premium Trading Days“) following the completion of the Warrant Repricing the closing price of the Company’s Shares exceeds $1.08, the Amended Warrants’ expiry date will be accelerated such that holders will have thirty (30) calendar days to exercise the Amended Warrants (if they have not first expired in the normal course) (the “Acceleration Clause“). The activation of the Acceleration Clause will be announced by press release and the 30-day period will commence seven (7) days after the last Premium Trading Day.

The Warrant Repricing is subject to the prior consent of all Warrantholders and the approval of the TSXV (“Warrant Amendment Approval“). The Company intends to issue an updating news release upon receipt, if any, of Warrant Amendment Approval.

Shares for Debenture Debt Settlement

The Company intends to offer a shares for debt settlement to all holders of unsecured convertible debentures issued pursuant to its January 16, 2025 private placement (the “Debentures“), to settle the outstanding principal amount owing under the Debentures, in the aggregate amount of up to $2,585,000 in consideration for: (i) the issuance of up to an aggregate of up to approximately 3,692,860 Shares (the “Settlement Shares“) at a deemed price of $0.70 per Settlement Share, and (ii) a cash payment of all accrued and unpaid interest up to the date of issuance of the Settlement Shares.

The Settlement Shares will be subject to a statutory hold period expiring four months and one day from the date of issuance, in accordance with applicable securities laws and TSXV policies.

Closing of the Shares for Debenture Debt Settlement is subject to the execution of definitive settlement documentation with any accepting holders of Debentures and the approval of the TSXV. The Company intends to issue an updating news release upon closing of the Shares for Debenture Debt Settlement.

MI 61-101 Compliance

It is anticipated that: (i) insiders of the Company may participate in the LIFE Offering, and any Units issued to insiders will be subject to a four month hold period pursuant to applicable policies of the TSXV; (ii) insiders of the Company may participate in the Warrant Repricing (subject to the rules and policies of the TSXV); and (iii) insiders of the Company may participate in the Shares for Debenture Debt Settlement, and any Settlement Shares issued to insiders will be subject to a four month hold period pursuant to applicable policies of the TSXV.

The issuance of Units to any insiders, the participation of any insiders in the Warrant Repricing, and the issuance of Settlement Shares to any insiders will be considered a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61- 101“). In respect of any such insider participation, the Company expects to rely on exemptions from the formal valuation requirements of MI 61-101 pursuant to section 5.5(a) and the minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(a), as the fair market value of the transaction, insofar as it involves interested parties, does not exceed 25% of the Company’s market capitalization.

Not an Offer to Sell or Solicitation in the US

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the 1933 Act, or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Forward-looking statements in this press release, including statements about: certain proposed financing transactions and the intended use of proceeds, and are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: risks relating to the Company’s ability to complete the proposed financing transactions on the terms and timeline contemplated herein, or at all, including the receipt of final approvals from the TSXV and satisfaction of other closing conditions, and those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved.

MustGrow Biologics Corp. (MGROF) – Another Arrow in the Quiver

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, June 11, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another Arrow. Yesterday, MustGrow added another arrow to its NexusBioAg product quiver with the signing of a distribution agreement with Phospholutions Inc., whereby MustGrow will sell Phospholutions’ RhizoSorb product in Canada. The new agreement further broadens NexusBioAg’s product offerings in Canada.

RhizoSorb. Phospholutions’ mission is to enhance global phosphorus use, a critical fertilizer for food production. Phosphorus is the second most used nutrient in global food production. RhizoSorb was developed to cut costs and reduce the environmental impact of fertilizer use by releasing nutrients in the soil more efficiently. The product has been through over 500 trials, including over 400 field trials. Notably, Phospholutions has signed a distribution agreement with The Andersons (NASDAQ:ANDE) for RhizoSorb distribution in the U.S.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – MustGrow and Phospholutions Sign Canadian Distribution Agreement for Phosphorous Efficiency Product – RhizoSorb®

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MGROF

  • Distribution agreement in Canada under MustGrow’s sales and distribution division NexusBioAg.
  • RhizoSorb® releases nutrients in the soil more efficiently to reduce phosphorus use by up to 50% while maximizing crop yield.
  • Sustainable production and responsible use of phosphorus is critical to support global food demands.

SASKATOON, Saskatchewan, Canada, June 10, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”), a leading provider of biological and regenerative agriculture solutions, is pleased to announce the addition of Phospholutions Inc.’s (“Phospholutions”) RhizoSorb® phosphorous efficiency product. MustGrow and Phospholutions have signed a distribution agreement whereby MustGrow will sell RhizoSorb® through its Canadian sales and distribution division, NexusBioAg (website: NexusBioAg).

Traditionally, the majority of applied phosphates are quickly tied up in soil, making them unavailable for plant uptake. As little as 10% of conventional phosphorus fertilizer is used by the crop. RhizoSorb® offers a controlled release, avoiding tie up while decreasing nutrient leaching.

RhizoSorb® Product Highlights1

RhizoSorb® patented technology is designed to replace conventional commodity fertilizers like monoammonium phosphate (“MAP”) and diammonium phosphate (“DAP”), by enhancing nutrient use efficiency through its integration into dry-granule phosphate production. It offers the same ease of application as traditional granular fertilizers, requiring no changes to existing equipment or practices.

RhizoSorb® increases phosphorus efficiency by up to 50%, allowing farmers to apply half the applied phosphorus of their traditional fertilizer while maintaining, and even improving yield. This efficiency translates to better grower return on investment, with potential savings of up to US$20 per acre by optimizing fertilizer inputs and reducing costs without sacrificing yield.

In addition to economic benefits, RhizoSorb® delivers meaningful environmental advantages, reducing CO₂e emissions by 45.2%, phosphorus runoff by 78%, and leaching by 84% compared to conventional MAP fertilizer.

“With approximately 94.5 million acres of crop production that depend on phosphate, Canada is a key market,” said Craig Dick, VP Sales and Marketing. “We are proud to partner with MustGrow to deliver RhizoSorb® to retailers and growers across Canada.”

“This partnership marks another major milestone in Phospholutions’ journey,” added Hunter Swisher, CEO of Phospholutions. “Partnering to bring more cost-effective fertilizer solutions to the Canadian market supports our broader global expansion efforts.”

“MustGrow and Phospholutions share a common mission to improve the global food system through sustainable production solutions,” said Colin Bletsky, COO of MustGrow. “Phosphorus is the second-most-used nutrient in global food production, making its efficient and responsible use a top priority for both our companies and the growers we serve.”

Benefits of Reduced-Rate Phosphate

RhizoSorb® features a 38% lower salt index, promoting healthier soils and long-term productivity. Growers benefit from lower application rates, reduced input costs, and sustained yields. For retailers, it offers reduced storage and logistics costs along with stronger margins. Environmentally, RhizoSorb® cuts CO₂ emissions by reducing carbon-intensive ingredients during manufacturing, reducing logistics across import, retail, and farm.

About Phospholutions Inc. 

Phospholutions’ mission is to enhance global phosphorus use. It believes that sustainable production and responsible use of phosphorus is critical to support global food demands. RhizoSorb® was developed to cut costs and reduce the environmental impact of fertilizer use by releasing nutrients in the soil more efficiently. Phospholutions’ patented fertilizer is incorporated into production to create higher efficiency products that maximize the use of phosphate resources. For further details, please visit www.phospholutions.com.

About MustGrow

MustGrow is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers.  In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products.  These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers.  Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies.  The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg.  MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted.  For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Forward-looking statements in this press release, including statements about the ability of RhizoSorb®  to reduce costs, environmental impacts, and strengthen retailer profit margins, are subject to a number of risks and uncertainties that may cause the actual results of MustGrow and its distributed products to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include the accuracy of the information provided by Phospholutions Inc. regarding RhizoSorb® as well as those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved.

1 All statements contained in this press release about product efficacy of RhizoSorb® and conventional phosphorus fertilizer are based on information from Phospholutions about their field testing RhizoSorb® in over 500 trials across 14 states for four years.

MustGrow Biologics Corp. (MGROF) – A Pivotal Milestone; Reports 1Q25 Results

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, May 29, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Milestone Quarter. MustGrow’s 1Q25 was a pivotal milestone in the Company’s evolution, with the Company recording its first full quarter since the NexusBioAg acquisition at the end of 2024. MustGrow reported significant sales revenue for the first time, although higher expenses resulting from the acquisition drove a higher net loss.

1Q25 Results. Revenue totaled $3.78 million (all figures are Canadian $), compared to our $2.6 million estimate and zero in the year ago quarter. Gross margin was 14.3%, below our estimated 19.2%. MustGrow recorded a net loss of $1.6 million, or a loss of $0.03/sh, versus our estimate of a loss of $570,000, or a loss of $0.01/sh. In 1Q24, the Company reported a loss of $1.0 million, or a loss of $0.02/sh.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – MustGrow Announces Record Q1-2025 Results:$3.8 Million Revenue, 14.3% Gross Profit Margin,$4.4 Million in Cash and Inventory

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MGROF

Investor Webcast: Wednesday, May 28th at 4:00pm ET / 1:00pm PT

Register/View Here: https://us02web.zoom.us/webinar/register/6217478678603/WN_h8uMVWINQsmS3HWF8K59Wg

Please join/register at least 5 minutes prior to the call.

Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.

SASKATOON, Saskatchewan, Canada, May 27, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended March 31, 2025. For complete details, please refer to the Q1-2025 Condensed Interim Financial Statements and associated Management’s Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company’s website: www.mustgrow.ca.

Key Financial Highlights:

  • Sales revenue of $3.8 million was recorded in Q1-2025 vs. zero in Q1-2024
  • Gross profit of $541,221 (14.3% gross profit margin) in Q1-2025(1)
  • Cash and equivalents on hand as at March 31, 2025 was $2.0 million with Inventory of $2.4 million
  • Net loss for the three-month period ended March 31, 2025 was $1.6 million and the net loss per share was $0.03 (basic) for the same period

“Our 2025 first quarter marked a pivotal milestone for MustGrow, reflecting the first full quarter of revenue since the acquisition of the NexusBioAg sales and distribution business on December 31, 2024,” stated Corey Giasson, President and CEO of MustGrow. “$3.8 million is a meaningful revenue figure for us, and with additional products already secured for the NexusBioAg distribution platform and increasing commercial farmer interest in our TerraSanteTM U.S. biofertility product, we are accelerating our mission to improve the global food system through sustainable production solutions.”

The Company continues to focus on capital allocation that generates revenue and revenue growth of both its NexusBioAg Canadian sales and distribution business and TerraSanteTM biofertility sales in the United States.

In the first quarter, MustGrow secured access to several additional agriculture products through its NexusBioAg sales and distribution platform in Canada, including a five-year exclusive distribution agreement with Adjuvants Plus Inc. (a Canadian regenerative agriculture company) and the addition of three new biological solutions to its product lines designed to enhance crop health, boost yield potential, and improve environmental resilience: EZ-Gro Max, EZ-Gro Cyto, and Rootella® mycorrhizal inoculants. MustGrow is continually working on securing new and meaningful products for Canadian farmers. More information is available on the NexusBioAg website: nexusbioag.com.

Notes:

  1. Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company’s results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: the receipt of final approval by the TSXV and those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved.

MustGrow Biologics Corp. (MGROF) – Reports 4Q25 Results

Posted on by cpereira@noblefcm.com


Tuesday, April 29, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

4Q25 Results. Revenue totaled CAD$118,836, reflecting initial sales of TerraSante product. We were at $25,000. Net loss totaled $1.2 million, or a loss of $0.02/sh, in line with our estimate. For the full year, MustGrow reported revenue of $398,018 and a net loss of $4.9 million, or a loss of $0.09/sh, also in line with our expectations.

Capital Raise. In mid-January, MustGrow raised $2.585 million of capital through the sale of convertible debentures. Combined with the $3 million of cash at year-end, we believe the Company has sufficient liquidity until significant revenue begins, which we expect this year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MustGrow Biologics Corp. (MGROF) – Reports 4Q25 Results

Posted on by cpereira@noblefcm.com


Monday, April 28, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

4Q25 Results. Revenue totaled $118.8 million, reflecting initial sales of TerraSante product. We were at $25,000. Net loss totaled $1.2 million, or a loss of $0.02/sh, in line with our estimate. For the full year, MustGrow reported revenue of $398,018 and a net loss of $4.9 Million, or a loss of $0.09/sh, also inline with our expectations.

Capital Raise. In mid-January, MustGrow raised $2.585 million of capital through the sale of convertible debentures. Combined with the $3 million of cash at year-end, we believe the Company has sufficient liquidity until significant revenue begins, which we expect this year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – MustGrow Adds New Biostimulants and Inoculants to Canadian Product Portfolio

Posted on by aweinsoff@channelchek.com

Research News and Market Data MGROF

SASKATOON, Saskatchewan, Canada, April 1, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow”), a leading provider of biological and regenerative agriculture solutions, is pleased to announce the addition of three cutting-edge biological solutions to MustGrow’s existing Canadian product lines through its recently acquired Canadian sales and distribution division, NexusBioAg. Product website linked here: NexusBioAg.

MustGrow now proudly offers three new biological solutions designed to enhance crop health, boost yield potential, and improve environmental resilience. Featuring EZ-Gro Max, EZ-Gro Cyto, and Rootella® mycorrhizal inoculants, these innovative products provide farmers with powerful, science-backed tools to maximize every acre.

“At MustGrow, we are committed to accelerating the adoption of biological solutions in agriculture. With this new product lineup, we are offering Canadian farmers proven, science-driven products that support sustainable farming while delivering strong agronomic performance,” said Colin Bletsky, COO of MustGrow.

EZ-Gro Max: Maximize Every Acre

Powered by Bio-APP™ Technology, EZ-Gro Max is a next-generation biostimulant designed to enhance foliar nutrition, improve plant growth, and increase yield potential while mitigating environmental stress.

Key Benefits:

  • Contains a five-biostimulant stack that promotes plant growth and development
  • Enhances crop yield potential
  • Reduces the effects of heat, drought, and other environmental stresses
  • Compatible with most foliar nutrition and chemistry partners

EZ-Gro Max is designed for Alfalfa, Barley, Canola, Corn, Oats, Potatoes, Rye, Soybeans, and Wheat, ensuring broad-spectrum benefits across multiple crop types.

EZ-Gro Cyto: Power Through the Unpredictable

Designed to help crops thrive under drought, heat, cold, and salinity stress, EZ-Gro Cyto is a stacked biostimulant package that proactively preserves yield potential in unpredictable conditions.

Key Benefits:

  • Features a four-biostimulant stack to improve resistance to environmental stresses
  • Activates plant disease resistance traits
  • Stimulates plant growth and development
  • Increases the number and size of flowers, grains, and pods

EZ-Gro Cyto is optimized for Alfalfa, Barley, Canola, Chickpeas, Corn, Lentils, Oats, Peas, Rye, Soybeans, Sunflower, and Wheat, making it an essential tool for growers facing variable weather conditions.

Rootella®: Highly Effective Mycorrhizal Inoculants

Developed by Groundwork BioAg®, Rootella mycorrhizal inoculants enhance root networks by forming fungal mycelia that increase plants’ ability to absorb water and nutrients. Built on more than 30 years of research, these highly efficient inoculants improve plant fertility, resilience, and sustainability.

Key Benefits:

  • Improved nutrient uptake, leading to increased yield and quality
  • Fertilizer and water savings, reducing input costs without compromising yield
  • Enhanced stress resilience, including drought, flooding, salinity, and extreme pH soils
  • Supports environmental sustainability through carbon sequestration

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers.  In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products.  These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers.  Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies.  The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg.  MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 51.6 million common shares issued and outstanding and 59.7 million shares fully diluted.  For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: the receipt of final approval by the TSXV and those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved

MustGrow Biologics Corp. (MGROF) – Exclusive Distribution Agreement Signed

Posted on by cpereira@noblefcm.com


Wednesday, February 12, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Distribution. Yesterday, MustGrow announced the signing of a five-year exclusive distribution agreement with Adjuvants Plus Inc., in which MustGrow will distribute Adjuvants’ product line across Canada through NexusBioAg. In addition, MustGrow has a First Right of Refusal for the distribution of Adjuvants’ product line in the U.S. market.

Complementing Products. Four key products are being introduced by Adjuvants in the agreement, with a particular focus on EndoFine and EndoGuard. Adjuvants’ patented Clonostachys rosea, a fungus that provides plant health and protection benefits, is in both products, offering an abundance of advantages for various crops in North America, such as corn, soybeans, pulses, canola, and fruits and vegetables. In our view, products such as EndoFine and EndoGuard complement MustGrow’s product line, as both lines target similar crops while offering health and protection benefits.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – MustGrow Announces Closing of Private Placement of Units for $2,585,000

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on MGROF

SASKATOON, Saskatchewan, Canada, January 16, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow“) is pleased to announce the closing of the previously announced non-brokered private placement of units (each, a “Unit“) at a price per Unit of $1,000 for aggregate gross proceeds to the Company of $2,585,000 (the “Private Placement“) on January 16, 2025 (the “Closing Date“).

Each Unit is comprised of: (i) $1,000 principal amount of unsecured convertible debentures (the “Debentures“); and (ii) 666 common share purchase warrants (the “Unit Warrants“). Each Debenture may, at the option of the holder: (i) be converted into common shares in the capital of the Company (the “Common Shares“) at price of $1.50 per Common Share (the “Principal Conversion Price“) at any time; or (ii) paid in cash 60 months following the Closing Date (subject to certain acceleration rights). Each Unit Warrant is exercisable by the holder thereof to acquire one Common Share at a price of $1.90 per Common Share for a period of 60 months following the Closing Date. The Debentures accrue interest at a rate of 8% per annum, payable semi-annually in cash.

If, at any time following the date that is 12 months from the Closing Date, the daily volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the “TSXV“) is greater than $3.00 for the preceding 30 consecutive trading days, the Company shall have the option to immediately accelerate the conversion of the Debentures at the Principal Conversion Price.

In connection with the Private Placement, certain finders received an aggregate cash fee of $67,200. In addition, the Company issued to certain finders an aggregate of 44,800 non-transferable finder’s warrants (the “Finder Warrants“). Each Finder Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of $1.90 per Common Share for a period of 24 months following the Closing Date.

The Company intends to use the proceeds from the Private Placement for inventory production for TerraSanteTM, working capital and general corporate purposes.

The Debentures, the Unit Warrants, the Finder Warrants, and any underlying Common Shares issued pursuant to those securities are subject to a four month plus one day hold period from the Closing Date. The Private Placement remains subject to final approval of the TSX Venture Exchange (the “TSXV“).

Certain insiders of the Company have subscribed for 300 Units under the Private Placement for aggregate gross proceeds of $300,000. Each subscription by an “insider” is considered to be a “related party transaction” for purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). The Company did not file a material change report more than 21 days before the Closing Date as the details of the Private Placement and the participation therein by each “related party” of the Company were not settled until shortly prior to the closing of the Private Placement, and the Company wished to close the Private Placement on an expedited basis for sound business reasons. The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. The Company is exempt from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on section 5.5(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Company’s market capitalization. Additionally, the Company is exempt from minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(b) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Company’s market capitalization.

This press release does not constitute, and shall not be construed as, an offer to sell or a solicitation of an offer to buy any Units within the United States.

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through on the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a public traded company (TSXV-MGRO) and has approximately 51.6 million common shares issued and outstanding and 59.2 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: the receipt of final approval of the TSXV; and the use of proceeds from the Private Placement. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: the receipt of final approval by the TSXV and those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved.

MustGrow Biologics Corp. (MGROF) – Completes Acquistion of NexusBioAg

Posted on by cpereira@noblefcm.com


Monday, January 06, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Acquisition Finalized. MustGrow announced the execution and closing of an Asset Purchase Agreement of assets representing NexusBioAg. The purchase price consists of (i) a deferred cash payment of approximately CAD$1,662,000, subject to adjustment in accordance with the terms of the APA; and (ii) earn-out payments equal to a specified percentage amount of gross margin on certain itemized products sold by MGRO in 2025 and 2026.

Financial Impact. Based on historical sales figures, management noted that NexusBioAg brings roughly CAD$15-$20 million of revenue annually to MustGrow and expects this to continue into 2025 and 2026. While no comment was made about the NexusBioAg’s margins, the expectation is that the Nexus side will be cashflow breakeven for 2025 as revenue stays the course. EBITDA is expected to be positive by 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – MustGrow Biologics Completes Acquisition of NexusBioAg

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on MGROF

SASKATOON, Saskatchewan, Canada, January 2, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow“) is pleased to announce the execution and closing of an Asset Purchase Agreement (the “APA“) dated December 31, 2024 with Univar Solutions Canada Ltd. (“Univar Solutions“) for the acquisition of certain assets that represent NexusBioAg (“NexusBioAg“).

MustGrow’s acquisition of NexusBioAg positions the Company as a fully integrated provider of biological and regenerative agriculture solutions with a sales, marketing and distribution division in Canada and the opportunity to expand the division’s operations into the U.S. The consideration payable to Univar Solutions pursuant to the APA is (i) a deferred cash payment of approximately $1,662,000.00, subject to adjustment in accordance with the terms of the APA; and (ii) earn-out payments equal to a specified percentage amount of gross margin on certain itemized products sold by MGRO in 2025 and 2026. There are no finder fees payable in connection with the acquisition and the parties are acting at arm’s length. The TSX Venture Exchange has conditionally approved the acquisition, subject to customary post-closing requirements.

Under MustGrow, this division will market and sell the existing NexusBioAg product lines, MustGrow’s owned products and technology, and potentially other third-party products. The NexusBioAg sales and marketing team brings extensive experience in the biological and regenerative agriculture sector to MustGrow’s operations, supported by a broad industry network that is uniquely positioned to drive growth and innovation. The NexusBioAg team has well-established relationships with growers, channel partners, and industry influencers. They are adept at commercialization of new biological and regenerative products as well as at leveraging a proven business model. The Company expects significant sales synergies from the acquisition driven by enhanced market access and reduced distribution costs for MustGrow’s owned products and technology.

“This synergistic acquisition solidifies MustGrow’s position as a fully integrated biological and regenerative agriculture company with an established sales, marketing and distribution division offering the existing NexusBioAg product lines and supporting the commercialization of MustGrow’s own innovative products and technologies. Just like MustGrow’s own products and technologies, we are committed to growing the NexusBioAg division and we welcome the new team to MustGrow,” said Corey Giasson, President & CEO of MustGrow.

About NexusBioAg

NexusBioAg, a division of MustGrow, provides an expanded portfolio of crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. With a diverse collection of inventory and logistics experts, procurement, customer service, agronomists, and sales and marketing experts, NexusBioAg strives to help meet increasingly unique agricultural businesses’ needs. Through these strong capabilities, a collaborative team-oriented approach, and a commitment to agricultural integrity, NexusBioAg is helping customers innovate and grow. Learn more at www.nexusbioag.com.

About MustGrow

MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through on the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a public traded company (TSXV-MGRO) and has approximately 51.6 million common shares issued and outstanding and 55.7 million shares fully diluted. For further details, please visit www.mustgrow.ca.

Contact Information

Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

MustGrow Forward-Looking Statements

Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: the potential expansion of the NexusBioAg division’s operations in the U.S.; the precise quantum of the consideration payable to Univar Solutions pursuant to the APA; whether the NexusBioAg division will market and sell the existing NexusBioAg product lines, MustGrow’s owned products and technology, and potentially other third-party products; and the expected significant sales synergies from the acquisition driven by enhanced market access and reduced distribution costs for MustGrow’s owned products and technology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will occur at all or have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: any required adjustments to the consideration payable to Univar Solutions pursuant to the APA (in accordance with the terms of the APA); the successful integration of the NexusBioAg division into MustGrow’s existing operations; changes to market conditions as a result of lower farm revenues due to lower yield because of weather events or lower crop prices, delayed planting due to weather impacting the application of additional technologies, reduced farm gate cash flow or credit ratings, higher farm input costs due to inflation, supply chain issues in production and shipping, increased competition from new products or lower prices for competing products, retail consolidation in the agribusiness sector, labour market issues, and third party product supply issues; and the risks described in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.

© 2025 MustGrow Biologics Corp. All rights reserved.